Ionpath

Ionpath has developed advanced ion beam imaging technology to revolutionize cancer diagnosis, with the aim of contributing to the improvement of human health. This innovation enables the precise examination of tissue biopsies, surpassing the capabilities of light microscopy. By catering to various tissue states, including fresh, frozen, or FFPE, Ionpath's technology significantly enhances the capability of healthcare providers to diagnose cancer effectively. Established in 2014, Ionpath operates within the Biotechnology and Health Care industries. Their commitment to innovation and impact is evident from their recent Corporate Round investment on 11 May 2022, with Thermo Fisher Scientific being their investing partner. Overall, Ionpath's cutting-edge technology and strategic partnerships position the company as a promising player in the healthcare industry, with potential for significant impact and growth.